Registry to Track Safety and Effectiveness of AtriCure Devices Used for Open, Hybrid, and Thoracoscopic Ablation Procedures Managing Atrial Fibrillation

What this Trial Is About

This research aims to gather real-world data on the safety and effectiveness of AtriCure devices used in different types of cardiac ablation procedures and left atrial appendage LAA management for patients with atrial fibrillation. The study will enroll up to 10,000 patients from multiple regions including the US, Canada, Europe, and Asia Pacific, without preselection bias. It is an observational registry to track outcomes over a long period. Participants will receive AtriCures open concomitant surgical ablation, hybrid convergent ablation, hybrid totally thoracoscopic ablation, or LAA exclusion procedures as part of their cardiac care. The study does not require additional visits or procedures beyond standard care. Patients are followed for up to ten years after their procedure according to the practices of their enrolling center. During the follow-up, researchers will monitor patients atrial fibrillation burden six months after ablation and record any adverse events related to the ablation procedure within one year. There are no additional study visits monitoring is based on routine clinical care. This allows for long-term data collection on treatment outcomes and safety in a real-world setting.

Tracking Results of Ablations to Combat AF Registry Generation 2